Advertisement

Imipenem Cilastatin Injection

[04 May 2016]

Products Affected - Description

Primaxin injection, Merck
250 mg/ 250 mg, vial, 25 count (NDC 00006-3514-58) - discontinued
500 mg/500 mg, vial, 25 count (NDC 00006-3516-59) - discontinued
500 mg/500 mg, vial, 25 count (NDC 00006-3516-59)
250 mg/ 250 mg, vial, 25 count (NDC 00006-3514-58)
 
Imipenem and Cilastatin Sodium injection, Fresenius Kabi
250 mg/250 mg, vial, 25 count (NDC 63323-0349-25)
500 mg/500 mg, vial, 25 count (NDC 63323-0322-25)
 
Imipenem and Cilastatin Sodium injection, Hospira
250 mg/ 250 mg, vial, 25 count (NDC 00409-3508-01)
500 mg/500 mg, vial, 25 count (NDC 00409-3507-01)

Reason for the Shortage

  • Fresenius Kabi has imipenem and cilastatin sodium injection on shortage due to increased demand.
  • Hospira has imipenem and cilastatin sodium injection on shortage due to manufacturing delays.
  • Merck has Primaxin vials on shortage due to increased demand. Merck has discontinued Primaxin ADD-Vantage vials.

Available Products

Imipenem and Cilastatin Sodium injection, Fresenius Kabi
250 mg/250 mg, vial, 10 count (NDC 63323-0349-20)
500 mg/500 mg, vial, 10 count (NDC 63323-0322-20)

Estimated Resupply Dates

  • Fresenius Kabi has imipenem and cilastatin 250 mg/250 mg vials and 500 mg/500 mg vials in 25 count sizes on back order and the company estimates a release date of mid-June 2016.
  • Hospira has imipenem and cilastatin 250 mg/250 mg vials and 500 mg/500 mg vials in 25 count sizes on back order and the company estimates a release date of late-May 2016.
  • Merck has Primaxin 500 mg/500 mg vials on intermittent back order with regular releases.

Updated

May 4, April 12, February 25 and 3, January 13, 2016; December 17, November 20 and 11, October 27 and 12, September 16, August 21 and 4, July 10, June 11 and 8, May 13, 2015, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement
ASHP Product Listing